Pharming awarded patent for human C1 inhibitor

By Lisa Kerner

Charlotte, N.C., June 29 - Pharming Group NV said the U.S. Patent and Trademark Office issued U.S. Patent No. 7,067,713 to the company for its lead product recombinant human C1 inhibitor (rhC1INH).

The patent, which allows equivalent patent applications by European and Australian patent offices, includes claims covering the production of rhC1INH in milk of transgenic mammals and in the treatment C1 inhibitor deficiency.

"Pharming is building further commercial value for rhC1INH by obtaining patents in these major territories," chief executive officer Francis Pinto said in a company news release.

"We are excited by these developments as well as with the progress on rhC1INH and look forward to upcoming regulatory submissions for the treatment of HAE (hereditary angioedema)."

Located in Leiden, The Netherlands, Pharming develops protein products for genetic disorders and surgical indications.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.